NRF hires the mind behind Barclays radical panel shake-up to launch legal ops consulting arm

Stéphanie Hamon

Norton Rose Fulbright (NRF) is making an ‘offensive move’ against the Big Four on legal operations consulting with the hire of the well-regarded former Barclays’ head of external engagement, Stéphanie Hamon (pictured).

The firm announced today (9 July) that Hamon, who quit the bank earlier this year, will join as a fee-earner in August to head the new practice and help ‘in-house departments function like a business’. Continue reading “NRF hires the mind behind Barclays radical panel shake-up to launch legal ops consulting arm”

Ashurst set to reach £1m PEP target after 31% surge as revenue tops £641m

Paul Jenkins

Paul Jenkins, Ashurst’s indomitable managing partner, is aiming to reach profit per equity partner (PEP) of £1m in the next financial year as the City stalwart unveils its best financial results to date.

On the back of three consecutive years of growth, the firm added £77m to its top line to hit £641m for the year to 30 April 2019, a significant 14% increase on the £564m turnover of last year. Continue reading “Ashurst set to reach £1m PEP target after 31% surge as revenue tops £641m”

The hard sell

‘I have never instructed a Big Four firm on a legal matter,’ says one UK general counsel of a large multinational. ‘The accountants’ legal offering is not something I’m close to,’ concedes Tesco GC Adrian Morris. The respective legal chiefs at The Royal Bank of Scotland (RBS) and Lloyds Banking Group strike a similar note: ‘We don’t currently use any of them,’ says Michael Shaw, while Kate Cheetham notes: ‘Our use of these offerings is quite limited.’ Continue reading “The hard sell”

Broader horizons – GCs taking outside roles

One of the set-piece debates of day one of Enterprise GC covered a pressing issue for GCs – how to widen their skillset by gaining board experience, as well as practical tips on becoming a non-executive director (NED) in particular. The session, chaired by veteran City columnist James Ashton, featured some seasoned campaigners: Michael Coates, associate general counsel for Shell UK and a director for a number of Shell companies; Eversheds Sutherland partner Denise Jagger, who has a portfolio of non-executive directorships and trustee roles; Stuart Morton, head of the legal and professional services function at executive search firm Odgers Berndtson; and Rob Webb QC, now a senior adviser at Brunswick and former general counsel for both British Airways and Rolls-Royce, who has held a number of board roles throughout his career.
Continue reading “Broader horizons – GCs taking outside roles”

Getting on with it: resilient market provides growth for Scottish independents

Nick Scott

Scottish independents Brodies and Shepherd and Wedderburn have continued their strong growth tracks despite ongoing uncertainty.

Brodies, Scotland’s largest firm, had a particularly strong year, as revenue rose 12% to £76.9m and profit came in at £37.4m, up 14%. This was up on the previous year’s flat growth of 3% and 4% respectively, with revenue up 49% over the last five years. Continue reading “Getting on with it: resilient market provides growth for Scottish independents”

In-house: Severn Trent open to extending panel beyond Eversheds’ sole-adviser role

Bronagh Kennedy

Severn Trent group general counsel (GC) Bronagh Kennedy (pictured) is keeping an open mind as to how many firms will be appointed to its £8m legal panel, with Eversheds Sutherland currently the company’s sole adviser.

The FTSE 100 water company has opened a tender process for the legal panel it last reviewed in 2015, when Eversheds extended the sole-adviser mandate it has held since 2010. The existing panel covers five lots but the new panel will be divided into three, covering all the companies in the Severn Trent Group. Continue reading “In-house: Severn Trent open to extending panel beyond Eversheds’ sole-adviser role”

Tougher competition – the growing impact of antitrust marquee deals

A key morning session of our 2019 Corporate and M&A Summit saw Linklaters London competition head Nicole Kar chair a lively debate between two authorities on European competition law and policy and its effect on M&A. On one side was economist Dr Claudio Calcagno, a vice president at Analysis Group and an expert in the competition arena, while on the other side sat John Gray, partner at Finsbury and head of its competition practice, who focuses on public affairs aspects of merger control cases, both in the UK and the EU.

Continue reading “Tougher competition – the growing impact of antitrust marquee deals”

Auctions – how to play the game

The final session before lunch in our Corporate and M&A Summit looked at the mechanics of auctions and how best to handle the competitive bid process from both the buyer’s and seller’s perspective. The session, moderated by co-chair of Greenberg Traurig’s global corporate practice, Fiona Adams, brought together panelists experienced in the auction process. Joining Adams was colleague Paul Maher, veteran corporate lawyer and vice chair of Greenberg, along with Jessie Gill, head of legal at Stemcor; Chris Hunt, group head of M&A for Rentokil Initial; and Nick Johnston, partner at Perella Weinberg. Continue reading “Auctions – how to play the game”

Big pharma, small partners: the key transactional trends in life sciences

Given that mega mergers coming out of the pharmaceutical and life sciences sector have dominated the corporate agenda for decades, it was fitting that an afternoon session of our inaugural Corporate and M&A Summit focused on transactional trends in this area. Chaired by Laura Anderson, co-chair of Bristows life sciences group, it gathered a collection of in-house experts from big pharma. Continue reading “Big pharma, small partners: the key transactional trends in life sciences”

Big pharma, small partners: the key transactional trends in life sciences

Given that mega mergers coming out of the pharmaceutical and life sciences sector have dominated the corporate agenda for decades, it was fitting that an afternoon session of our inaugural Corporate and M&A Summit focused on transactional trends in this area. Chaired by Laura Anderson, co-chair of Bristows life sciences group, it gathered a collection of in-house experts from big pharma. Continue reading “Big pharma, small partners: the key transactional trends in life sciences”